Unveiling the Scale of Typhoid's Economic Toll in India

Typhoid fever, caused by the bacterium Salmonella Typhi, remains a persistent public health challenge in India, where contaminated water and food facilitate its spread. A groundbreaking study published in The Lancet Regional Health - Southeast Asia has quantified the staggering economic impact of this disease, particularly driven by antimicrobial resistance (AMR). The research estimates that in 2023 alone, typhoid fever imposed a national economic burden of INR 123 billion (approximately US$1.5 billion), with antibiotic-resistant strains accounting for a whopping 87% of these costs. This figure encompasses direct medical expenses, productivity losses, and other indirect costs, highlighting the urgent need for targeted interventions.

The study, led by researchers including Vittal Mogasale from the London School of Hygiene & Tropical Medicine (LSHTM) in collaboration with Indian institutions like the Public Health Foundation of India and Christian Medical College (CMC) Vellore, utilized a decision-tree model to dissect these costs. By integrating data from surveillance projects such as the Surveillance for Enteric Fever in India (SEFI) and national census projections, it provides a comprehensive view disaggregated by age, state, and resistance patterns.

Understanding Typhoid Fever and the Rise of AMR

Typhoid fever manifests with symptoms like high fever, abdominal pain, and weakness, often requiring hospitalization in severe cases. In India, it affects millions annually, with a companion modeling study estimating 4.9 million cases, 730,000 hospitalizations, and 7,850 deaths in 2023. Fluoroquinolone-resistant (FQR) strains, once the go-to antibiotics like ciprofloxacin, now dominate, comprising 82% of hospitalizations and 88% of deaths among treatment seekers.

AMR occurs when bacteria evolve to withstand antibiotics, prolonging illness, increasing treatment complexity, and escalating costs. FQR typhoid patients face unit costs 1.5 to 2 times higher than susceptible strains, driving the disproportionate burden. This resistance trend, noted since the early 2010s, has shifted treatment to alternatives like azithromycin or ceftriaxone, which are costlier and not always effective.

Key Findings: 87% Driven by Resistant Strains

Of the total INR 123 billion burden, FQR infections contributed INR 107 billion. Direct out-of-pocket expenses (OOPE) totaled INR 109.6 billion, while productivity losses added INR 42.6 billion under the human capital approach. Public health systems bore only INR 13 billion, or 9% of the total, underscoring the heavy reliance on private care.

Non-hospitalized cases, five times more prevalent, accounted for 4.4 times the economic load due to sheer volume. The average unit cost per typhoid patient was INR 26,514, rising to INR 33,082 for hospitalized FQR cases. Households shouldered 91% of expenses, pushing 70,000 families into catastrophic health expenditure—defined as costs exceeding 40% of non-food income.

Children Under 10 Bear the Brunt

Young children, especially those aged 5-9 years, incurred over 60% of the total costs in one scenario, reflecting higher incidence and hospitalization rates. Under-10s contributed more than half the national burden, with FQR amplifying complications like intestinal perforation. This age group faces prolonged recovery, schooling disruptions, and caregiver productivity losses, perpetuating cycles of poverty.

In urban hotspots, where sanitation lags despite progress, children are particularly vulnerable. The study urges prioritizing this demographic in vaccination drives, as current oral vaccines are less effective for under-2s, but typhoid conjugate vaccines (TCV) offer robust protection from six months.

State-Wise Disparities: Hotspots Emerge

Maharashtra, Uttar Pradesh, Andhra Pradesh (including Telangana), Tamil Nadu, and West Bengal accounted for 51% of costs. Delhi, Maharashtra, and Karnataka topped FQR burden at 29% nationally, with prevalence exceeding 70% in some areas. These states, often urban-dense, report higher notification due to better diagnostics but likely underrepresent rural realities.

Variations stem from population density, WASH infrastructure gaps, and surveillance differences. For instance, Uttar Pradesh's sheer size amplifies absolute numbers, while Maharashtra's urban clusters drive per capita costs.

Photo by Bhupathi Srinu on Unsplash

Breaking Down the Costs: Direct vs. Indirect

Direct costs dominated at 89%, split between OOPE for drugs (INR 24,945 average for non-hospitalized) and hospitalization (INR 31,057). Indirect costs, mainly lost wages, were substantial for working adults and caregivers. Under friction-cost method, productivity losses dropped 99.8%, but human capital estimates reveal long-term societal impact.

Private facilities handled most care, inflating expenses. Public systems, despite lower unit costs, serve fewer due to access barriers.

Methodological Rigor Behind the Numbers

The researchers employed probabilistic sensitivity analysis with 5,000 Monte Carlo simulations, drawing from SEFI (2017-2020), GBD 2021, and cost data inflated to 2023 values. Two scenarios addressed age-hospitalization uncertainty: GBD patterns vs. SEFI empirics. State projections used 2011 Census data scaled to 2023. This robust approach accounts for underreporting, estimated at 90% for community cases. For full details, read the original study.

Expert Perspectives and Indian Research Contributions

Prof. Jacob John from CMC Vellore emphasized, “With drug-resistant typhoid driving over 80% of hospitalisations, this is as much an economic crisis as medical.” Dr. Vijayalaxmi Mogasale added, “Out-of-pocket costs limit basic needs; vaccination and stewardship are key.”

CMC Vellore, a leader in enteric fever research, has conducted pivotal trials on TCV efficacy. Collaborations with LSHTM exemplify global-Indian academic synergy, informing policy.

Vaccination: The TCV Game-Changer

Typhoid conjugate vaccine (TCV), like Bharat Biotech's Typbar-TCV (WHO-prequalified), shows 79-85% efficacy in trials, suitable for infants. India, a manufacturing hub, could phase rollout in high-burden metros like Mumbai, mirroring Hepatitis B success. Gavi support aids low-income access, potentially averting millions of cases and billions in costs.

Nepal's TCV introduction slashed cases 80%; India plans national integration. Experts advocate 16-24 month dosing in routine immunization.

Multifaceted Solutions: Stewardship, WASH, and Insurance

Beyond vaccines, antimicrobial stewardship curtails overuse via diagnostics and guidelines. WASH improvements—safe water, sanitation—cut transmission at source. Expanding Ayushman Bharat reduces OOPE, preventing impoverishment. Integrated surveillance like ICMR's AMR network tracks trends.

Photo by Gayatri Malhotra on Unsplash

• Enhance rapid diagnostics for targeted therapy.
• Promote hygiene education in schools.
• Invest in wastewater monitoring, as piloted by CMC Vellore.

Policy Implications and Future Outlook

This study bolsters TCV inclusion in UIP, prioritizing children and hotspots. With India's 20% global typhoid share, domestic action yields international dividends. Ongoing research at institutions like PHFI and CMC will refine strategies. By 2030, combined interventions could halve burden, saving lives and economy. Visit LSHTM's summary for more insights.